PDCD1LG2 and hepatocellular carcinoma: These structural insights and our observation of the correlation of PD-L1 and PD-L2 suggest that the combined immunotherapy approaches targeting PD-L1, PD-L2 and PD-1 are warranted for advanced HCC management.